

Management of Immunotherapy-Related Toxicities, Ve Guidelines in Oncology

Journal of the National Comprehensive Cancer Network: JNCC
17, 255-289

DOI: [10.6004/jnccn.2019.0013](https://doi.org/10.6004/jnccn.2019.0013)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Thyroid disorders induced by checkpoint inhibitors. Reviews in Endocrine and Metabolic Disorders, 2018, 19, 325-333.	5.7	87
2	Immune checkpoint inhibitorsâ€”induced neuromuscular toxicity: From pathogenesis to treatment. Journal of the Peripheral Nervous System, 2019, 24, S74-S85.	3.1	42
3	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
4	Research Agenda of the Oncology Nursing Society: 2019â€”2022. Oncology Nursing Forum, 2019, 46, 654-669.	1.2	38
5	Systemic Therapy for Locally Advanced and Metastatic Nonâ€”Small Cell Lung Cancer. JAMA - Journal of the American Medical Association, 2019, 322, 764.	7.4	720
6	Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. Seminars in Cancer Biology, 2019, 59, 290-297.	9.6	78
7	Cardiovascular Toxicities of Immuneâ€”Checkpointâ€”Inhibitors. Journal of the American College of Cardiology, 2019, 74, 1714-1727.	2.8	124
8	Immune checkpoint inhibitorâ€”related luminal GI adverseâ€”events. Gastrointestinal Endoscopy, 2019, 90, 881-892.	1.0	24
9	Acute and Long-term Adverse Events Associated With Checkpoint Blockade. Seminars in Oncology Nursing, 2019, 35, 150926.	1.5	7
10	Immune Checkpoint Inhibitors in Lung Cancer and Melanoma. Seminars in Oncology Nursing, 2019, 35, 150932.	1.5	34
11	Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy. Case Reports in Oncological Medicine, 2019, 1-3.	0.3	9
12	Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instabilityâ€”High Tumors. Current Treatment Options in Oncology, 2019, 20, 83.	3.0	11
13	Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. , 2019, 7, 319.		164
14	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. Journal of Biomedical Science, 2019, 26, 96.	7.0	26
15	EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. Cancers, 2019, 11, 1954.	3.7	57
16	Immune-related dermatologic toxicities: to make a long story short. Cutaneous and Ocular Toxicology, 2020, 39, 10-12.	1.3	1
17	Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology, 2020, 159, 167-177.	4.4	75
18	Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy. Journal of Clinical Neuroscience, 2020, 71, 271-272.	1.5	3

#	ARTICLE	IF	CITATIONS
19	Immune-checkpoint inhibitors induced diarrhea and colitis. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 25-32.	2.3	21
20	Management of immune checkpoint inhibitor-related dermatologic adverse events. <i>Thoracic Cancer</i> , 2020, 11, 488-492.	1.9	17
21	Management of immune checkpoint inhibitor-related rheumatic adverse events. <i>Thoracic Cancer</i> , 2020, 11, 198-202.	1.9	2
22	Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 291-298.	1.1	21
23	Immune checkpoint inhibitor-associated myositis and myasthenia gravis overlap: Understanding the diversity in a case series. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 17, e262-e267.	1.1	3
24	Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7195.	4.1	55
25	Management of the Adverse Effects of Immune Checkpoint Inhibitors. <i>Vaccines</i> , 2020, 8, 575.	4.4	29
26	Drug-Induced Uveitis: Part 1. <i>Advances in Ophthalmology and Optometry</i> , 2020, 5, 265-306.	0.3	0
27	Tocilizumab and other targeted therapies for severe cutaneous immune-related adverse events. <i>British Journal of Dermatology</i> , 2020, 183, 613-613.	1.5	1
28	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	4.1	22
29	Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation. <i>Frontiers in Oncology</i> , 2020, 10, 1785.	2.8	35
30	Efficacy and immune-related adverse event associations in avelumab-treated patients. , 2020, 8, e001427.		16
31	Implementation of a pharmacy consult service for evaluation of immune checkpoint inhibitor related adverse events at a large community hospital. <i>Journal of Oncology Pharmacy Practice</i> , 2020, , 107815522097026.	0.9	1
32	How to manage patients with corticosteroids in oncology in the era of immunotherapy?. <i>European Journal of Cancer</i> , 2020, 141, 239-251.	2.8	52
33	MRI Findings of Immune Checkpoint Inhibitor-Induced Hypophysitis: Possible Association with Fibrosis. <i>American Journal of Neuroradiology</i> , 2020, 41, 1683-1689.	2.4	22
34	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. <i>Journal of Autoimmunity</i> , 2020, 114, 102514.	6.5	37
35	Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. <i>Targeted Oncology</i> , 2020, 15, 449-466.	3.6	86
36	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. <i>Lancet Oncology</i> , The, 2020, 21, e398-e404.	10.7	74

#	ARTICLE	IF	CITATIONS
37	Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board. <i>Targeted Oncology</i> , 2020, 15, 541-548.	3.6	6
38	Immune checkpoint inhibitor-related cutaneous adverse events. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e149-e153.	1.1	7
39	Management of Immune-Related Cutaneous Adverse Reactions to PD-1 and PD-L1 Inhibitors for the Inpatient Dermatologist. <i>Current Dermatology Reports</i> , 2020, 9, 231-243.	2.1	4
40	Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. <i>Journal of Immunotherapy</i> , 2020, 43, 291-298.	2.4	7
41	Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service. , 2020, 8, e000992.		4
42	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6159-6173.	2.2	11
43	Discordance between recommended and delivered therapies for immunotherapy-associated cutaneous toxicities in pediatric populations. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28653.	1.5	0
44	Immune Related Adverse Events. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 432-440.	2.0	4
45	Management of immunotherapy colitis: Special considerations in the COVID-19 era. <i>Cancer</i> , 2020, 126, 4630-4633.	4.1	4
46	Immunotherapy-Related Colitis: An Emerging Challenge and a Quest for Prospective Data. <i>JCO Oncology Practice</i> , 2020, 16, 464-465.	2.9	5
47	Strategies for improving the management of immune-related adverse events. , 2020, 8, e001754.		60
48	Transcriptional Regulation of Cancer Immune Checkpoints: Emerging Strategies for Immunotherapy. <i>Vaccines</i> , 2020, 8, 735.	4.4	18
49	Biomarkers in individualized management of chimeric antigen receptor T cell therapy. <i>Biomarker Research</i> , 2020, 8, 13.	6.8	23
50	Immune-related adverse events of checkpoint inhibitors. <i>Nature Reviews Disease Primers</i> , 2020, 6, 38.	30.5	684
51	Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol. <i>Thoracic Cancer</i> , 2020, 11, 2023-2030.	1.9	5
53	Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. <i>International Immunopharmacology</i> , 2020, 85, 106628.	3.8	14
54	Therapeutic strategies for virus-negative myocarditis: a comprehensive review. <i>European Journal of Internal Medicine</i> , 2020, 77, 9-17.	2.2	30
55	Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy. , 2020, 8, e000898.		3

#	ARTICLE	IF	CITATIONS
56	Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 547-555.	0.6	9
57	Advances in the Treatment of Non-Small Cell Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 237-247.	2.1	50
58	Pulmonary Complications of Immunotherapy. <i>Clinics in Chest Medicine</i> , 2020, 41, 295-305.	2.1	1
59	Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. <i>Kidney International Reports</i> , 2020, 5, 1139-1148.	0.8	71
60	Brief Communication: Immune Checkpoint Inhibitor-induced Diaphragmatic Dysfunction: A Case Series. <i>Journal of Immunotherapy</i> , 2020, 43, 104-106.	2.4	6
61	Neurologic complications of immune checkpoint inhibitors. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 479-488.	2.4	82
62	A Fatal Case of Pembrolizumab-Induced Myocarditis in Non-Small Cell Lung Cancer. <i>JACC: Case Reports</i> , 2020, 2, 426-430.	0.6	7
63	Immunotherapy for metastatic cancer patients: the current status, limitations, obstacles and future directions. <i>Annals of Palliative Medicine</i> , 2020, 9, 121-125.	1.2	1
64	Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. <i>Hepatology</i> , 2020, 72, 315-329.	7.3	131
65	Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 171-177.	3.1	32
66	Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review. <i>JCO Oncology Practice</i> , 2020, 16, 453-461.	2.9	42
67	Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus. <i>Journal of Thoracic Oncology</i> , 2020, 15, e29-e30.	1.1	2
68	Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency. , 2020, 8, e000463.		8
69	Renal immune-related adverse events of immune checkpoint inhibitor. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 305-311.	1.1	6
70	Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer. <i>Immunology Letters</i> , 2020, 221, 61-71.	2.5	12
71	Recognition and management of the gastrointestinal and hepatic immune-related adverse events. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 95-102.	1.1	6
72	Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. <i>Annals of Neurology</i> , 2020, 87, 659-669.	5.3	137
73	Complications neurologiques des immunothérapies anti-cancéreuses: une pathologie émergente. <i>Pratique Neurologique - FMC</i> , 2020, 11, 60-68.	0.1	0

#	ARTICLE	IF	CITATIONS
74	Atypical Presentations and Management of Endocrine and Hepatic Immune-Related Adverse Events From Adjuvant Immune Checkpoint Inhibitor Therapy in Stage III Resected Melanoma. <i>JCO Oncology Practice</i> , 2020, 16, 10s-14s.	2.9	1
75	Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. <i>Thoracic Cancer</i> , 2020, 11, 805-809.	1.9	8
76	Management of immune checkpoint inhibitor-related adverse events: A review of case reports. <i>Thoracic Cancer</i> , 2020, 11, 498-504.	1.9	10
77	Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1393-1403.e1.	4.4	47
78	Immunotherapy and Targeted Drugs for Common Cancers. <i>Journal for Nurse Practitioners</i> , 2020, 16, 195-200.	0.8	0
79	Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment. <i>Clinical and Translational Oncology</i> , 2020, 22, 1923-1937.	2.4	14
80	Autoimmune complications of immunotherapy: pathophysiology and management. <i>BMJ, The</i> , 2020, 369, m736.	6.0	79
81	An update on the safety of nivolumab for the treatment of advanced melanoma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 409-421.	2.4	5
82	Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 662-668.	1.9	18
83	Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1690-1702.	2.4	26
84	Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 250-250.	1.7	42
85	Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. <i>Blood Advances</i> , 2020, 4, 676-686.	5.2	101
86	Reply to Y. Inagaki et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 1749-1750.	1.6	1
87	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48.	0.9	153
88	Diabetes mellitus induced by immune checkpoint inhibitors. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3366.	4.0	12
89	PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 546-553.	3.3	49
90	Advances on immune-related adverse events associated with immune checkpoint inhibitors. <i>Frontiers of Medicine</i> , 2021, 15, 33-42.	3.4	24
91	Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 492-506.	0.8	42

#	ARTICLE	IF	CITATIONS
92	Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 113-134.	9.4	40
93	Patterns of cutaneous immune-related adverse events in adults and children with advanced sarcoma: a retrospective cohort study. <i>British Journal of Dermatology</i> , 2021, 184, 363-365.	1.5	0
94	Case series review of neuroradiologic changes associated with immune checkpoint inhibitor therapy. <i>Neuro-Oncology Practice</i> , 2021, 8, 247-258.	1.6	3
95	Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Arthritis and Rheumatology</i> , 2021, 73, 866-874.	5.6	56
96	Pembrolizumab rechallenge in squamous non-small-cell lung cancer and HIV-positivity: a case report. <i>Immunotherapy</i> , 2021, 13, 277-281.	2.0	1
97	Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies. <i>Critical Care Clinics</i> , 2021, 37, 47-67.	2.6	5
98	Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications. <i>Arthritis and Rheumatology</i> , 2021, 73, 553-565.	5.6	21
99	Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy. <i>Nano Today</i> , 2021, 36, 101023.	11.9	45
100	Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 1089-1099.	3.6	37
101	Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor-induced gastroenterocolitis. <i>European Journal of Cancer</i> , 2021, 142, 143-146.	2.8	6
102	A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease. <i>Kidney International Reports</i> , 2021, 6, 66-77.	0.8	84
103	Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 203-211.	1.8	42
104	Brain Stem Encephalitis in a Patient With Recurrent Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor: Case Presentation and Review of the Literature. <i>Cureus</i> , 2021, 13, e13034.	0.5	8
105	Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience. <i>Translational Lung Cancer Research</i> , 2021, 10, 415-429.	2.8	13
106	Fatal Immune Checkpoint Inhibitor-related Pancreatitis. <i>Internal Medicine</i> , 2021, 60, 3905-3911.	0.7	15
107	GI Toxicities from Cancer Therapy. , 2021, , 341-379.		0
108	Durvalumab-associated Late-onset Myocarditis Successfully Treated with Corticosteroid Therapy. <i>Internal Medicine</i> , 2022, 61, 527-531.	0.7	6
109	Ipilimumab in Melanoma: An Evergreen Drug. , 2021, , 217-235.		0

#	ARTICLE	IF	CITATIONS
110	Atezolizumab-induced encephalitis in a patient with metastatic breast cancer: a case report and review of neurological adverse events associated with checkpoint inhibitors. <i>Autopsy and Case Reports</i> , 2021, 11, e2021261.	0.6	8
111	Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2197-2207.	4.2	31
112	Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). <i>Journal of Hematology and Oncology</i> , 2021, 14, 12.	17.0	40
113	Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021, 8, 18.	1.6	3
114	The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110177.	2.5	3
115	Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 611366.	4.8	41
116	Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment. <i>Neoplasia</i> , 2021, 23, 189-196.	5.3	38
117	CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department. <i>Clinical Toxicology</i> , 2021, 59, 376-385.	1.9	4
118	CT imaging findings of anti-PD-1 inhibitor-related enterocolitis.. <i>Abdominal Radiology</i> , 2021, 46, 3033-3043.	2.1	4
119	Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. , 2021, 9, e001884.		27
120	Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer. <i>Cancer Science</i> , 2021, 112, 1506-1513.	3.9	14
121	Clinical and biochemical markers in CIPN: A reappraisal. <i>Revue Neurologique</i> , 2021, 177, 890-907.	1.5	5
122	Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 604227.	2.8	12
123	Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2789-2800.	2.5	11
124	Immune Checkpoint Inhibitor-related Guillain-Barré Syndrome: A Case Series and Review of the Literature. <i>Journal of Immunotherapy</i> , 2021, 44, 276-282.	2.4	17
126	Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis. <i>Nature Communications</i> , 2021, 12, 1439.	12.8	39
127	Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1301-1306.	2.9	12
128	Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 897-907.	1.9	66

#	ARTICLE	IF	CITATIONS
129	Systemic Therapy of Metastatic Melanoma: On the Road to Cure. <i>Cancers</i> , 2021, 13, 1430.	3.7	50
130	Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single-center experience. <i>Cancer Medicine</i> , 2021, 10, 2978-2986.	2.8	2
131	Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy. <i>Frontiers in Neurology</i> , 2021, 12, 642800.	2.4	26
132	Acute pancreatitis without abdominal pain induced by administration of nivolumab and ipilimumab. <i>Modern Rheumatology Case Reports</i> , 2021, 5, 425-430.	0.7	6
133	Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. , 2021, 9, e002292.		25
134	Endocrine toxicities of immune checkpoint inhibitors. <i>Nature Reviews Endocrinology</i> , 2021, 17, 389-399.	9.6	162
135	Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events. <i>Kidney International Reports</i> , 2021, 6, 1022-1031.	0.8	54
136	Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis. <i>Current Opinion in Urology</i> , 2021, 31, 332-339.	1.8	9
137	Progressive Pulmonary Infiltrates in a Man with Mediastinal Lymphoma. <i>Annals of the American Thoracic Society</i> , 2021, 18, 884-888.	3.2	1
138	Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13604.	3.4	18
139	Neurological complications of immune checkpoint inhibitor cancer immunotherapy. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117424.	0.6	14
140	Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer. <i>JAMA Dermatology</i> , 2021, 157, 577.	4.1	31
141	Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 605941.	2.8	7
142	Infectious Challenges with Novel Antibody-Based Therapies. <i>Current Infectious Disease Reports</i> , 2021, 23, 1.	3.0	0
143	What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. <i>Current Treatment Options in Oncology</i> , 2021, 22, 53.	3.0	2
144	Delayed thrombocytopenia as a rare but serious adverse event secondary to immune checkpoint inhibitor: a case report. <i>Annals of Palliative Medicine</i> , 2021, 10, 33-33.	1.2	9
145	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2653.	3.7	2
146	Recognition and Management of Toxicities from Immunotherapy and Targeted Therapy in Elderly Patients with Lung Cancer. <i>Advances in Oncology</i> , 2021, 1, 73-84.	0.2	0

#	ARTICLE	IF	CITATIONS
147	The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2021, 26, e1205-e1215.	3.7	10
148	Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity. <i>British Journal of Dermatology</i> , 2021, 185, 627-635.	1.5	12
149	Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. <i>Cancer Treatment Reviews</i> , 2021, 97, 102187.	7.7	31
150	Cardiac Magnetic Resonance in Cardio-Oncology. <i>JACC: CardioOncology</i> , 2021, 3, 191-200.	4.0	6
151	The Comprehensive "Omics" Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6932.	4.1	9
152	Managing side effects of immune checkpoint inhibitors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103354.	4.4	15
153	Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103351.	4.4	24
154	The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2752-2765.	2.8	5
155	Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies. <i>Diagnostics</i> , 2021, 11, 1187.	2.6	10
156	Kidney injury associated with antitumor therapy: focus on the adverse events of modern immuno-oncological drugs. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 649-660.	0.8	0
157	Limitations of morphology-based management for immune checkpoint inhibitor-related cutaneous adverse events. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e281-e282.	1.2	2
158	Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 662731.	2.8	10
159	Immune checkpoint inhibitors-related encephalitis in melanoma and non-melanoma cancer patients: a single center experience. <i>Supportive Care in Cancer</i> , 2021, 29, 7563-7568.	2.2	8
160	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. , 2021, 9, e002552.		16
161	Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Targeted Oncology</i> , 2021, 16, 553-568.	3.6	13
162	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
163	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 495-508.	46.4	120
164	Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103376.	4.4	9

#	ARTICLE	IF	CITATIONS
165	Cancer Care Continuum Research and Educational Innovation: Are Academic Internists Keeping up with Population Trends?. <i>Journal of Cancer Education</i> , 2023, 38, 28-33.	1.3	1
166	Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. , 2021, 9, e002896.		20
167	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 417-431.	4.2	6
168	Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. <i>Oral Diseases</i> , 2022, 28, 9-22.	3.0	17
169	Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases. <i>BioMed Research International</i> , 2021, 2021, 1-17.	1.9	10
170	Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies. <i>Journal of Immunotherapy</i> , 2021, 44, 325-334.	2.4	12
171	Imaging Features of Pulmonary Immune-related Adverse Events. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1449-1460.	1.1	8
172	Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e858-e867.	1.6	26
173	Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 730320.	4.8	39
174	Usage Patterns and Incidence of Thyroid-related Adverse Events in Patients Treated with PD-1 Inhibitors. <i>Korean Journal of Clinical Pharmacy</i> , 2021, 31, 188-197.	0.3	0
175	Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: A Comprehensive Review, Part II. <i>Southern Medical Journal</i> , 2021, 114, 614-619.	0.7	2
176	Histopathologically confirmed lichenoid eruptions from immune checkpoint inhibitor therapy: a retrospective cohort analysis. <i>British Journal of Dermatology</i> , 2021, , .	1.5	1
177	Immunotherapy for Head and Neck Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1021-1037.	2.2	8
178	Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 160, 121-127.	1.9	6
179	Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy. <i>American Journal of Emergency Medicine</i> , 2021, 50, 51-58.	1.6	6
180	Immune checkpoint inhibitors: An emergency medicine focused review. <i>American Journal of Emergency Medicine</i> , 2021, 50, 335-344.	1.6	5
181	New Onset Ocular Myasthenia Gravis After Pembrolizumab Therapy: a Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 309-311.	0.6	3
183	Miscellaneous Rheumatic Syndromes. , 2021, , 169-189.		0

#	ARTICLE	IF	CITATIONS
185	Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1939-1949.	4.2	27
186	SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 213-222.	2.4	14
187	Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1047-1059.	3.1	9
188	The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs). <i>Thoracic Cancer</i> , 2020, 11, 835-839.	1.9	43
189	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
190	Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit. <i>Annals of Intensive Care</i> , 2020, 10, 143.	4.6	24
191	Anticancer Drugs and the Nervous System. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 732-764.	0.8	13
192	Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy. <i>Archives of Endocrinology and Metabolism</i> , 2020, 64, 483-486.	0.6	13
193	Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy. <i>Kidney360</i> , 2020, 1, 16-24.	2.1	42
194	Inclusion of Anesthesiologists and Surgeons While Developing Guidelines for Management of Immune-Related Adverse Events. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 56-57.	1.4	1
195	Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 750-757.	4.9	86
196	Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1287-1290.	4.9	5
197	Immune-Mediated Toxic Epidermal Necrolysis. <i>Cureus</i> , 2020, 12, e9587.	0.5	6
198	Quality of Life and Symptom Management in Advanced Biliary Tract Cancers. <i>Cancers</i> , 2021, 13, 5074.	3.7	14
199	Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management. <i>Kidney Medicine</i> , 2021, 3, 1074-1081.	2.0	26
200	GI Toxicities from Cancer Therapy. , 2020, , 1-39.		0
202	Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis. <i>Frontiers in Immunology</i> , 2021, 12, 768957.	4.8	22
203	Association between PD-L1 inhibitor, tumor site and adverse events of potential immune etiology within the USFDA adverse event reporting system. <i>Immunotherapy</i> , 2021, 13, 1407-1417.	2.0	2

#	ARTICLE	IF	CITATIONS
204	Hepatobiliary Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 271-276.	1.6	3
205	F-18 FDG PET Tests in Skin Cancer Including Malignant Melanoma. , 2021, , 119-134.		0
207	Cancer des voies aérodigestives et supérieures. , 2020, , 178-189.e4.		0
208	Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators. <i>Journal of Cancer Metastasis and Treatment</i> , 2020, 2020, .	0.8	3
209	Immunotherapy for Metastatic Urothelial Cancer. , 2021, , 201-213.		0
210	Systemic Treatment in Advanced Melanoma. <i>Updates in Surgery Series</i> , 2021, , 167-174.	0.1	0
211	Diabetic Ketoacidosis: An Adverse Reaction to Immunotherapy. <i>Cureus</i> , 2020, 12, e10632.	0.5	2
213	Immune-related Pulmonary Toxicity From Cancer Immunotherapy: A Systematic Approach. <i>Clinical Pulmonary Medicine</i> , 2020, 27, 183-192.	0.3	0
216	Diagnosis and Management of Immune Checkpoint Inhibitor Colitis. <i>Gastroenterology and Hepatology</i> , 2021, 17, 358-366.	0.1	3
217	Gastrointestinal adverse events of immunotherapy. <i>BJR Open</i> , 2021, 3, .	0.6	0
218	Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management. <i>Dermatology and Therapy</i> , 2022, 12, 29-40.	3.0	17
219	Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 710943.	3.5	6
220	A review of neurotoxicities associated with immunotherapy and a framework for evaluation. <i>Neuro-Oncology Advances</i> , 2021, 3, v108-v120.	0.7	6
221	Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China. <i>Frontiers in Oncology</i> , 2021, 11, 757993.	2.8	23
222	Development of a Flow Cytometry Assay to Predict Immune Checkpoint Blockade-Related Complications. <i>Frontiers in Immunology</i> , 2021, 12, 765644.	4.8	5
224	Hepatobiliary and Pancreatic Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 339-355.	1.6	6
225	Adverse events of immunotherapy in non-small cell lung cancer: A systematic review and network meta-analysis. <i>International Immunopharmacology</i> , 2022, 102, 108353.	3.8	19
226	Pembrolizumab Induced Acute Tubulointerstitial Nephritis. <i>American Journal of Therapeutics</i> , 2020, Publish Ahead of Print, .	0.9	2

#	ARTICLE	IF	CITATIONS
227	Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	1.3	1
228	Harnessing big data to characterize immune-related adverse events. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 269-280.	27.6	41
229	Continuous blood purification successfully treated severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy: A case report. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29563.	1.5	2
230	Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 163-180.	2.0	12
231	Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs). <i>Current Oncology</i> , 2022, 29, 267-282.	2.2	1
232	Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 203-213.	2.4	4
233	Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. <i>Lancet Oncology</i> , The, 2022, 23, 220-233.	10.7	106
234	Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features. <i>Journal of Immunotherapy</i> , 2022, 45, 217-221.	2.4	5
235	Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 252-259.	1.9	4
236	Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management. <i>Frontiers in Immunology</i> , 2021, 12, 800879.	4.8	54
237	Strategies to mitigate the toxicity of cancer therapeutics. <i>Advances in Cancer Research</i> , 2022, , 215-244.	5.0	5
238	Neurologic complications of immune modulatory therapy. , 2022, , 537-551.		0
239	Chemotherapy-induced peripheral neuropathy. , 2022, , 515-519.		0
240	Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice. <i>Neurological Sciences</i> , 2022, 43, 2339-2361.	1.9	16
241	Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era. <i>Cells</i> , 2022, 11, 770.	4.1	26
242	Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review. <i>Immunotherapy</i> , 2022, , .	2.0	4
243	Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models. <i>Immunology and Allergy Clinics of North America</i> , 2022, 42, 285-305.	1.9	4
244	Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2597-2608.	4.2	25

#	ARTICLE	IF	CITATIONS
245	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. <i>Frontiers in Immunology</i> , 2022, 13, 804597.	4.8	27
246	Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors. <i>Journal of Immunotherapy</i> , 2022, 45, 210-216.	2.4	15
247	CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 593-605.	4.1	31
248	Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy. <i>Frontiers in Endocrinology</i> , 2022, 13, 779915.	3.5	15
249	Clinical features of hepatic dysfunction caused by immune checkpoint inhibitors and treatment of refractory cases. <i>Acta Hepatologica Japonica</i> , 2022, 63, 107-119.	0.1	0
250	Nivolumab Combined With Ipilimumab Treatment Induced Hypophysitis and Immune-Mediated Liver Injury in Advanced Esophageal Squamous Cell Carcinoma: A Case Report. <i>Frontiers in Oncology</i> , 2022, 12, 801924.	2.8	1
251	Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1458-1460.	2.4	5
252	Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients. <i>Clinical Imaging</i> , 2022, 86, 31-37.	1.5	0
253	Immunotherapy-Related Acute Kidney Injury. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 429-437.e1.	1.4	5
254	Treatment of acute kidney injury in cancer patients. CKJ: <i>Clinical Kidney Journal</i> , 2022, 15, 873-884.	2.9	6
255	Pembrolizumab-induced erythema multiforme requiring systemic immunosuppression. <i>Internal Medicine Journal</i> , 2021, 51, 2149-2150.	0.8	1
256	Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. <i>Cancers</i> , 2021, 13, 6109.	3.7	9
257	Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review. <i>Journal of Neuro-Oncology</i> , 2022, 157, 533-550.	2.9	7
260	Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events. <i>Current Oncology</i> , 2022, 29, 3104-3117.	2.2	4
261	Advanced materials for management of immune-related adverse events induced by immune checkpoint inhibitors. <i>Materials and Design</i> , 2022, 219, 110738.	7.0	0
262	Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer. <i>International Immunopharmacology</i> , 2022, 108, 108803.	3.8	5
263	Pembrolizumab-induced Myasthenia Gravis: Literature Review of Ocular Manifestations and a Refractory Case. <i>Journal of Immunotherapy</i> , 2022, Publish Ahead of Print, .	2.4	4
264	Role of Abdominal and Pelvic CT Scans in Diagnosis of Patients with Immunotherapy-Induced Colitis. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, 5, 32-36.	1.4	1

#	ARTICLE	IF	CITATIONS
265	Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment. <i>Cancers</i> , 2022, 14, 2687.	3.7	10
266	Acupuncture Treatment of Guillain-Barré Syndrome After Using Immune Checkpoint Inhibitors: A Case Report. <i>Frontiers in Neurology</i> , 2022, 13, .	2.4	7
267	Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?. <i>Immunotherapy Advances</i> , 2022, 2, .	3.0	15
268	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. <i>Molecules</i> , 2022, 27, 3798.	3.8	29
269	Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors. <i>American Journal of Clinical Dermatology</i> , 0, , .	6.7	3
270	Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	6
271	Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram. <i>Lung Cancer</i> , 2022, 170, 74-84.	2.0	7
272	A Case of Immune-related Renal Failure in Response to Chemo-immunotherapy Combinations That Was Successfully Treated with Steroid Therapy and Temporary Hemodialysis. <i>Japanese Journal of Lung Cancer</i> , 2022, 62, 221-226.	0.1	1
273	Pulmonary adverse events following immune checkpoint inhibitors. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 391-398.	2.6	9
274	Multidisciplinary approach to treatment with immune checkpoint inhibitors in patients with HIV, tuberculosis, or underlying autoimmune diseases. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	1
275	Musculoskeletal and Neurological Complications of Check Point Inhibitors. , 2023, , 207-214.		0
276	Imaging features of toxicities associated with immune checkpoint inhibitors. <i>European Journal of Radiology Open</i> , 2022, 9, 100434.	1.6	6
277	Immune checkpoint inhibitors in cancer therapy: Review of orofacial adverse events and role of the oral healthcare provider. <i>Frontiers in Oral Health</i> , 0, 3, .	3.0	4
278	Severe infections in recipients of cancer immunotherapy: what intensivists need to know. <i>Current Opinion in Critical Care</i> , 2022, 28, 540-550.	3.2	5
279	Camrelizumab-Related Lethal Arrhythmias and Myasthenic Crisis in a Patient with Metastatic Thymoma. <i>Case Reports in Cardiology</i> , 2022, 2022, 1-6.	0.2	5
280	Biologic Therapy for Refractory Immune Checkpoint Inhibitor Colitis. <i>Biologics: Targets and Therapy</i> , 0, Volume 16, 119-127.	3.2	1
281	Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events. <i>Clinical Lung Cancer</i> , 2022, 23, 686-693.	2.6	7
282	The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	2

#	ARTICLE	IF	CITATIONS
283	The CURB65 score predicted 180-day mortality of non-small cell lung carcinoma patients with immune checkpoint inhibitor-associated pneumonitis: A pilot retrospective analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0
284	<i>Hepatology (Liver and Bile Duct)</i> , 2022, , 119-165.		0
285	<i>Rheumatology (Arthritis and Myositis)</i> , 2022, , 301-313.		0
286	Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist. <i>Current Clinical Pathology</i> , 2022, , 91-111.	0.0	0
287	<i>Endocrine</i> , 2022, , 59-79.		0
288	Severe Immune-Related Adverse Events: A Case Series of Patients Needing Hospital Admission in a Spanish Oncology Referral Center and Review of the Literature. <i>Diagnostics</i> , 2022, 12, 2116.	2.6	1
289	Systemic Sclerosis Association with Malignancy. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 398-416.	6.5	7
290	Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI. , 2022, 10, e005646.		12
291	Immunotherapy-Associated Uveitis. , 0, , .		0
292	PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
293	Drug-related immune-mediated myelopathies. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	1
294	Minding the Bathwater: Fertility and Reproductive Toxicity in the Age of Immuno-Oncology. <i>JCO Oncology Practice</i> , 0, , .	2.9	3
295	Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. <i>Nature Reviews Nephrology</i> , 2022, 18, 794-805.	9.6	20
296	An exploratory cross-sectional study of immune checkpoint inhibitors and immuno-related adverse events: Knowledge and influencing factors among Japanese oncology nurses. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2023, 10, 100147.	1.6	3
297	Cardiovascular disease and chimeric antigen receptor cellular therapy. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	1
298	Case report: Immune-mediated meibomian gland dysfunction following pembrolizumab therapy for advanced urothelial carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
299	Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2022, 18, 641-656.	8.0	37
300	Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management. <i>Cureus</i> , 2022, , .	0.5	1

#	ARTICLE	IF	CITATIONS
301	A Case Report of Immune Checkpoint Inhibitor-Induced Aortitis Treated with Tocilizumab. Case Reports in Immunology, 2022, 2022, 1-3.	0.4	6
302	Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge. , 0, 2, .		2
304	Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles. International Immunopharmacology, 2022, 113, 109300.	3.8	4
305	Immunotherapy in gynecologic malignancies. , 2023, , 506-520.e7.		0
306	Early onset delirium incidence and risk factors in hematology oncology patients admitted to the intensive care unit: A retrospective cohort study. International Journal of Critical Illness and Injury Science, 2022, 12, 190.	0.6	0
307	An Updated Focus on Immune Checkpoint Inhibitors and Tubulointerstitial Nephritis. , 2023, , 157-184.		0
308	Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. American Journal of Gastroenterology, 2022, 117, 1917-1932.	0.4	4
309	Immunogenomic correlates of immune-related adverse events for anti-“programmed cell death 1 therapy. Frontiers in Immunology, 0, 13, .	4.8	4
310	Seronegative rheumatoid arthritis after combination therapy with ipilimumab and nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma. IJU Case Reports, 0, , .	0.3	2
311	Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors. Medical Sciences (Basel, Switzerland), 2022, 10, 65.	2.9	0
312	Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis. Clinical and Experimental Immunology, 0, , .	2.6	2
313	Treatment of rheumatic adverse events of cancer immunotherapy. Best Practice and Research in Clinical Rheumatology, 2022, 36, 101805.	3.3	9
314	Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge. Frontiers in Medicine, 0, 9, .	2.6	1
315	Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors. Kidney International Reports, 2023, 8, 628-641.	0.8	11
316	Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis. Targeted Oncology, 2023, 18, 147-158.	3.6	2
317	Safety and short-term outcomes of laparoscopic surgery for advanced gastric cancer after neoadjuvant immunotherapy: A retrospective cohort study. Frontiers in Immunology, 0, 13, .	4.8	5
319	Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea. Journal of Cancer Research and Clinical Oncology, 2023, 149, 5583-5589.	2.5	6
321	Editorial Comment on Seronegative rheumatoid arthritis after combination therapy with Ipilimumab and Nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma. IJU Case Reports, 2023, 6, 105-106.	0.3	0

#	ARTICLE	IF	CITATIONS
323	Cutaneous Melanoma and Hormones: Focus on Sex Differences and the Testis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 599.	4.1	5
324	Immune checkpoint inhibitor-related pneumonitis and COVID-19: a case-matched comparison of CT findings. <i>Radiologia Medica</i> , 2023, 128, 212-221.	7.7	2
325	Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known. <i>Hepatology Communications</i> , 2023, 7, e0063-e0063.	4.3	3
326	Accelerating the Evolution of Immune-Related Enterocolitis Management. <i>Journal of Clinical Oncology</i> , 2023, 41, 3110-3115.	1.6	2
327	Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. <i>International Immunopharmacology</i> , 2023, 117, 109881.	3.8	8
328	Advances in treatments of patients with classical and emergent neurological toxicities of anticancer agents. <i>Revue Neurologique</i> , 2023, 179, 405-416.	1.5	0
330	Current landscape and tailored management of immune-related adverse events. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	1
331	A retrospective cohort study on the cardiotoxicity incidence rates of immune checkpoint inhibitors for oncology patients. <i>Journal of the Chinese Medical Association</i> , 2023, 86, 499-505.	1.4	8
332	Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	2
333	JCS 2023 Guideline on the Diagnosis and Treatment of Myocarditis. <i>Circulation Journal</i> , 2023, 87, 674-754.	1.6	14
334	Anti-cancer immune checkpoint inhibitor tolerability: summon up of savoir faire in 2023. <i>Annales D'Endocrinologie</i> , 2023, , .	1.4	0
335	Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis. <i>Investigational New Drugs</i> , 0, , .	2.6	0
336	Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor-associated cardiotoxicity. <i>ESC Heart Failure</i> , 2023, 10, 1907-1918.	3.1	3
337	Kidney function while on immune checkpoint inhibitors: Trends in incidence of acute kidney injury, and its causes and outcomes. <i>Journal of Onco-Nephrology</i> , 2023, 7, 57-65.	0.6	2
338	Gastrointestinal injury induced by immunomodulators: A review article. <i>Therapeutic Advances in Gastroenterology</i> , 2023, 16, 175628482311585.	3.2	0
339	Mortality associated with the development of acute liver failure after a single dose of nivolumab. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.8	1
340	Immune-related adverse events as independent prognostic factors for camrelizumab in patients with esophageal squamous cell carcinoma: a retrospective cohort study. <i>Journal of Gastrointestinal Oncology</i> , 2023, .	1.4	0
341	A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7630.	4.1	1

#	ARTICLE	IF	CITATIONS
342	Immune checkpoint inhibitors in cancer: a review. Japanese Journal of Cancer, 2023, 54, 1-14.	1.4	1
343	Toxicité des immunothérapies anti-cancer. Médecine/Sciences, 2023, 39, 445-451.	0.2	0
344	The Feasibility, Acceptability, and Effectiveness of Electronic Patient-Reported Outcome Symptom Monitoring for Immune Checkpoint Inhibitor Toxicities: A Systematic Review. JCO Clinical Cancer Informatics, 2023, , .	2.1	1
345	Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nature Reviews Clinical Oncology, 2023, 20, 527-542.	27.6	13
346	Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity. Clinical and Translational Oncology, 2023, 25, 3073-3085.	2.4	2
347	Better Late Than Never: The Impact of Steroidal Treatment on the Outcome of Melanoma Patients Treated with Immunotherapy. Cancers, 2023, 15, 3041.	3.7	5
348	Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors. International Urology and Nephrology, 0, , .	1.4	0
349	Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment. Leukemia and Lymphoma, 2023, 64, 1497-1499.	1.3	2
350	Evaluation of appendectomy as a potential risk factor for immune checkpoint inhibitor-associated enterocolitis. Immunotherapy, 0, , .	2.0	0
351	Neurologic Complications of Cancer Immunotherapy. Current Oncology, 2023, 30, 5876-5897.	2.2	0
352	Immune Checkpoint Inhibitor-Associated AKI: Debates in Diagnosis, Management, and Rechallenge. Seminars in Nephrology, 2022, 42, 1513-1516.	1.6	1
353	Update on Immune Checkpoint Inhibitor-Associated Uveitis. Current Ophthalmology Reports, 0, , .	1.2	0
354	Endocrine side effects of immune checkpoint inhibitors. Frontiers in Endocrinology, 0, 14, .	3.5	7
355	Immune Checkpoint Inhibitor-related Pancreatitis: A Case Series, Review of the Literature and an Expert Opinion. Journal of Immunotherapy, 2023, 46, 271-275.	2.4	3
356	Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus. International Immunopharmacology, 2023, 122, 110414.	3.8	2
357	Checkpoint Inhibitor-Induced Pneumonitis: Incidence and Management. Current Pulmonology Reports, 0, , .	1.3	0
358	A nomogram model for predicting the risk of checkpoint inhibitor-related pneumonitis for patients with advanced non-small cell lung cancer. Cancer Medicine, 2023, 12, 15998-16010.	2.8	1
359	Role of B cells in immune-related adverse events following checkpoint blockade. Immunological Reviews, 0, , .	6.0	2

#	ARTICLE	IF	CITATIONS
360	Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil. <i>Clinical Journal of Gastroenterology</i> , 2023, 16, 720-725.	0.8	2
361	Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	1
362	<scp>CD4</scp> T cells and toxicity from immune checkpoint blockade. <i>Immunological Reviews</i> , 2023, 318, 96-109.	6.0	3
363	Secondary Central Nervous System Demyelinating Disorders in the Elderly: A Narrative Review. <i>Healthcare (Switzerland)</i> , 2023, 11, 2126.	2.0	1
364	Clinical features and treatment outcomes of progressive uveal melanoma. <i>Archive of Clinical Cases</i> , 2023, 10, 102-106.	0.5	0
365	Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	5
366	Pembrolizumab-Induced Rhabdomyolysis in a Clear Cell Renal Cell Carcinoma Patient: A Case Report. <i>Case Reports in Oncology</i> , 2023, 16, 728-733.	0.7	1
367	International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors. <i>International Forum of Allergy and Rhinology</i> , 2024, 14, 149-608.	2.8	6
368	Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
369	Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma. <i>Melanoma Research</i> , 0, , .	1.2	0
370	Severe thyrotoxicosis induced by tislelizumab: a case report and literature review. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
373	Guillainâ€™Barre syndrome in children. <i>Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova</i> , 2023, 123, 20.	0.7	0
374	Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects. <i>Oncology Reviews</i> , 0, 17, .	1.8	1
375	Unveiling Therapeutic Targets for Esophageal Cancer: A Comprehensive Review. <i>Current Oncology</i> , 2023, 30, 9542-9568.	2.2	0
376	Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology. <i>Nefrologia</i> , 2023, 43, 622-635.	0.4	0
377	Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study. <i>RMD Open</i> , 2023, 9, e003795.	3.8	0
378	Life-Threatening Endocrinological Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy. <i>Cancers</i> , 2023, 15, 5786.	3.7	3
379	Immune Checkpoint Inhibition. , 2024, , 1-91.		0

#	ARTICLE	IF	CITATIONS
380	Baseline Circulating Blood Cell Counts and Ratios and Changes Therein for Predicting Immune-Related Adverse Events during Immune Checkpoint Inhibitor Therapy: A Multicenter, Prospective, Observational, Pan-Cancer Cohort Study with a Gender Perspective. <i>Cancers</i> , 2024, 16, 151.	3.7	0
381	Efficacy and Safety of Traditional Chinese Medicines as a Complementary Therapy Combined With Chemotherapy in the Treatment of Gastric Cancer: An Overview of Systematic Reviews and Meta-Analyses. <i>Integrative Cancer Therapies</i> , 2024, 23, .	2.0	0
382	The Clinical Analysis of Checkpoint Inhibitor Pneumonitis with Different Severities in Lung Cancer Patients: A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2024, 13, 255.	2.4	0
383	Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy. <i>Cancer Reports</i> , 2024, 7, .	1.4	1
384	Clinicopathological features of kidney injury in patients receiving immune checkpoint inhibitors (ICPi) combined with anti-vascular endothelial growth factor (anti-VEGF) therapy. <i>Journal of Clinical Pathology</i> , 0, , jcp-2023-209173.	2.0	0
385	Cancer immunotherapy-associated endocrine complications and treatment strategies. , 2024, , 199-221.		0
386	Liver Injury and Its Impact on Prognosis in Patients with HBV-Related Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 11, 207-217.	3.7	0
387	Thyroid disorders induced by immune checkpoint inhibitors. <i>Endocrine</i> , 0, , .	2.3	0
388	Immune-Related Adverse Events of Immune Checkpoint Inhibitors. <i>Annals of Internal Medicine</i> , 2024, 177, ITC17-ITC32.	3.9	1
389	Achillesâ€™ Heel of currently approved immune checkpoint inhibitors: immune related adverse events. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
390	New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis. <i>World Journal of Clinical Cases</i> , 0, 12, 1050-1062.	0.8	0
391	Immune checkpoint inhibitors and acute kidney injury. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
392	Immune-related adverse events in non-small cell lung cancer: Occurrence, mechanisms and therapeutic strategies. <i>Clinical and Translational Medicine</i> , 2024, 14, .	4.0	0
393	New advances in the study of PD-1/PD-L1 inhibitors-induced liver injury. <i>International Immunopharmacology</i> , 2024, 131, 111799.	3.8	0